On the public citation graph
Flipping the odds of drug development success through human genomics
0 signed · 150 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/jama.2013.282836openalex-snapshot
Varespladib and Cardiovascular Events in Patients With an Acute Coronary Syndrome
inferredcites →https://doi.org/10.1001/jama.2014.11061openalex-snapshot
Effect of Darapladib on Major Coronary Events After an Acute Coronary Syndrome
inferredcites →https://doi.org/10.1001/jama.2014.1717openalex-snapshot
Clinical Interpretation and Implications of Whole-Genome Sequencing
inferredcites →https://doi.org/10.1001/jamainternmed.2016.6008openalex-snapshot
Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results
inferredcites →https://doi.org/10.1002/14651858.cd011748.pub2openalex-snapshot
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease
inferredcites →https://doi.org/10.1002/9780470485408.ch1openalex-snapshot
Therapeutic Monoclonal Antibodies: Past, Present, and Future
inferredcites →https://doi.org/10.1002/hec.1538openalex-snapshot
Drug development costs when financial risk is measured using the Fama–French three‐factor model
inferredcites →https://doi.org/10.1007/978-1-62703-586-6_3openalex-snapshot
Therapeutic Human Monoclonal Antibodies in Inflammatory Diseases
inferredcites →https://doi.org/10.1016/0022-5193(69)90015-0openalex-snapshot
Metabolic stability and epigenesis in randomly constructed genetic nets
inferredcites →https://doi.org/10.1016/j.ajhg.2011.10.004openalex-snapshot
Abundant Pleiotropy in Human Complex Diseases and Traits
inferredcites →https://doi.org/10.1016/j.ajhg.2016.05.013openalex-snapshot
Contrasting the Genetic Architecture of 30 Complex Traits from Summary Association Data
inferredcites →https://doi.org/10.1016/j.cell.2017.05.038openalex-snapshot
An Expanded View of Complex Traits: From Polygenic to Omnigenic
inferredcites →https://doi.org/10.1016/j.drudis.2014.03.004openalex-snapshot
Towards a sustainable system of drug development
inferredcites →https://doi.org/10.1016/j.gde.2009.04.010openalex-snapshot
Common vs. rare allele hypotheses for complex diseases
inferredcites →https://doi.org/10.1016/j.jacc.2013.06.044openalex-snapshot
Secretory Phospholipase A2-IIA and Cardiovascular Disease
inferredcites →https://doi.org/10.1016/j.jacc.2015.10.056openalex-snapshot
Lipoprotein-Associated Phospholipase A 2 Loss-of-Function Variant and Risk of Vascular Diseases in 90,000 Chinese Adults
inferredcites →https://doi.org/10.1016/j.jacc.2015.12.060openalex-snapshot
Metabolomic Profiling of Statin Use and Genetic Inhibition of HMG-CoA Reductase
inferredcites →https://doi.org/10.1016/j.pharmthera.2007.05.002openalex-snapshot
Clinical attrition due to biased preclinical assessments of potential efficacy
inferredcites →https://doi.org/10.1016/s0140-6736(03)12715-8openalex-snapshot
Problems of reporting genetic associations with complex outcomes
inferredcites →https://doi.org/10.1016/s0140-6736(05)67767-7openalex-snapshot
Nature's randomised trials
inferredcites →https://doi.org/10.1016/s0140-6736(12)60110-xopenalex-snapshot
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis
inferredcites →https://doi.org/10.1016/s0140-6736(14)61183-1openalex-snapshot
HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials
inferredcites →https://doi.org/10.1016/s0168-9525(01)02410-6openalex-snapshot
On the allelic spectrum of human disease
inferredcites →https://doi.org/10.1016/s1474-4422(15)00178-7openalex-snapshot
Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study
inferredcites →https://doi.org/10.1017/s0080456800012163openalex-snapshot
XV.—The Correlation between Relatives on the Supposition of Mendelian Inheritance.
inferredcites →https://doi.org/10.1017/s0269889714000040openalex-snapshot
From Administrative Infrastructure to Biomedical Resource: Danish Population Registries, the “Scandinavian Laboratory,” and the “Epidemiologist's Dream”
inferredcites →https://doi.org/10.1038/201847a0openalex-snapshot
A Preliminary Estimate of the Number of Human Genes
inferredcites →https://doi.org/10.1038/ejhg.2013.274openalex-snapshot
GWAS Central: a comprehensive resource for the comparison and interrogation of genome-wide association studies
inferredcites →https://doi.org/10.1038/nature11307openalex-snapshot
TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis
inferredcites →https://doi.org/10.1038/nature22034openalex-snapshot
Human knockouts and phenotypic analysis in a cohort with a high rate of consanguinity
inferredcites →https://doi.org/10.1038/nbt.2786openalex-snapshot
Clinical development success rates for investigational drugs
inferredcites →https://doi.org/10.1038/nbt.3802openalex-snapshot
Overcoming cellular barriers for RNA therapeutics
inferredcites →https://doi.org/10.1038/ncomms14357openalex-snapshot
Connecting genetic risk to disease end points through the human blood plasma proteome
inferredcites →https://doi.org/10.1038/ncomms5684openalex-snapshot
Strong effects of genetic and lifestyle factors on biomarker variation and use of personalized cutoffs
inferredcites →https://doi.org/10.1038/ng.2261openalex-snapshot
Meta-analysis identifies six new susceptibility loci for atrial fibrillation
inferredcites →https://doi.org/10.1038/ng.2480openalex-snapshot
Large-scale association analysis identifies new risk loci for coronary artery disease
inferredcites →https://doi.org/10.1038/ng.2610openalex-snapshot
Identification of heart rate–associated loci and their effects on cardiac conduction and rhythm disorders
inferredcites →https://doi.org/10.1038/ng.3314openalex-snapshot
The support of human genetic evidence for approved drug indications
inferredcites →https://doi.org/10.1038/ng.3552openalex-snapshot
Genetic variants associated with subjective well-being, depressive symptoms, and neuroticism identified through genome-wide analyses
inferredcites →https://doi.org/10.1038/ng.3570openalex-snapshot
Detection and interpretation of shared genetic influences on 42 human traits
inferredcites →https://doi.org/10.1038/ng.3643openalex-snapshot
A reference panel of 64,976 haplotypes for genotype imputation
inferredcites →https://doi.org/10.1038/ng.3926openalex-snapshot
Bayesian analysis of genetic association across tree-structured routine healthcare data in the UK Biobank
inferredcites →https://doi.org/10.1038/ng.610openalex-snapshot
Estimation of effect size distribution from genome-wide association studies and implications for future discoveries
inferredcites →https://doi.org/10.1038/nm0810-837aopenalex-snapshot
Big pharma moves from 'blockbusters' to 'niche busters'
inferredcites →https://doi.org/10.1038/nmeth.2689openalex-snapshot
DGIdb: mining the druggable genome
inferredcites →https://doi.org/10.1038/nmeth.3288openalex-snapshot
The fickle P value generates irreproducible results
inferredcites →https://doi.org/10.1038/nrd.2015.17openalex-snapshot
Ten years of anti-vascular endothelial growth factor therapy
inferredcites →https://doi.org/10.1038/nrd.2016.230openalex-snapshot
A comprehensive map of molecular drug targets
inferredcites →https://doi.org/10.1038/nrd.2016.238openalex-snapshot
Cornerstones of CRISPR–Cas in drug discovery and therapy
inferredcites →https://doi.org/10.1038/nrd.2016.93openalex-snapshot
EMA greenlights second gene therapy
inferredcites →https://doi.org/10.1038/nrd1470openalex-snapshot
Can the pharmaceutical industry reduce attrition rates?
inferredcites →https://doi.org/10.1038/nrd2115openalex-snapshot
Angiogenesis: an organizing principle for drug discovery?
inferredcites →https://doi.org/10.1038/nrd2961openalex-snapshot
Lessons from 60 years of pharmaceutical innovation
inferredcites →https://doi.org/10.1038/nrd3078openalex-snapshot
How to improve R&D productivity: the pharmaceutical industry's grand challenge
inferredcites →https://doi.org/10.1038/nrd3375openalex-snapshot
Phase III and submission failures: 2007–2010
inferredcites →https://doi.org/10.1038/nrd3405openalex-snapshot
The productivity crisis in pharmaceutical R&D
inferredcites →https://doi.org/10.1038/nrd3439-c1openalex-snapshot
Believe it or not: how much can we rely on published data on potential drug targets?
inferredcites →https://doi.org/10.1038/nrd3478openalex-snapshot
Trends in the exploitation of novel drug targets
inferredcites →https://doi.org/10.1038/nrd3681openalex-snapshot
Diagnosing the decline in pharmaceutical R&D efficiency
inferredcites →https://doi.org/10.1038/nrd4051openalex-snapshot
Validating therapeutic targets through human genetics
inferredcites →https://doi.org/10.1038/nrd4090openalex-snapshot
Phase II and Phase III attrition rates 2011–2012
inferredcites →https://doi.org/10.1038/nrd4309openalex-snapshot
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
inferredcites →https://doi.org/10.1038/nrd4570openalex-snapshot
What does it take to produce a breakthrough drug?
inferredcites →https://doi.org/10.1038/nrg1916openalex-snapshot
A tutorial on statistical methods for population association studies
inferredcites →https://doi.org/10.1038/nrg3118openalex-snapshot
Rare and common variants: twenty arguments
inferredcites →https://doi.org/10.1038/nrg3377openalex-snapshot
The heritability of human disease: estimation, uses and abuses
inferredcites →https://doi.org/10.1038/nrg3461openalex-snapshot
Pleiotropy in complex traits: challenges and strategies
inferredcites →https://doi.org/10.1038/nri2763openalex-snapshot
Therapeutic antibodies: past, present and future
inferredcites →https://doi.org/10.1038/nrn3475openalex-snapshot
Power failure: why small sample size undermines the reliability of neuroscience
inferredcites →https://doi.org/10.1038/s41586-018-0175-2openalex-snapshot
Genomic atlas of the human plasma proteome
inferredcites →https://doi.org/10.1038/sj.clpt.6100479openalex-snapshot
The State of Innovation in Drug Development
inferredcites →https://doi.org/10.1056/nejmoa054013openalex-snapshot
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
inferredcites →https://doi.org/10.1056/nejmoa0706628openalex-snapshot
Effects of Torcetrapib in Patients at High Risk for Coronary Events
inferredcites →https://doi.org/10.1056/nejmoa1203572openalex-snapshot
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
inferredcites →https://doi.org/10.1056/nejmoa1315878openalex-snapshot
Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease
inferredcites →https://doi.org/10.1056/nejmoa1405386openalex-snapshot
Inactivating Mutations in NPC1L1 and Protection from Coronary Heart Disease
inferredcites →https://doi.org/10.1056/nejmoa1410489openalex-snapshot
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
inferredcites →https://doi.org/10.1056/nejmoa1607948openalex-snapshot
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
inferredcites →https://doi.org/10.1056/nejmp1311439openalex-snapshot
Expediting Drug Development — The FDA's New “Breakthrough Therapy” Designation
inferredcites →https://doi.org/10.1073/pnas.27.11.499openalex-snapshot
Genetic Control of Biochemical Reactions in Neurospora
inferredcites →https://doi.org/10.1080/09332480.2005.10722754openalex-snapshot
Why Most Published Research Findings Are False
inferredcites →https://doi.org/10.1086/321272openalex-snapshot
Are Rare Variants Responsible for Susceptibility to Complex Diseases?
inferredcites →https://doi.org/10.1093/bioinformatics/btq126openalex-snapshot
PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene–disease associations
inferredcites →https://doi.org/10.1093/hmg/ddu309openalex-snapshot
Multiple evidence strands suggest that there may be as few as 19 000 human protein-coding genes
inferredcites →https://doi.org/10.1093/ije/dyg070openalex-snapshot
‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease?*
inferredcites →https://doi.org/10.1093/ije/dys188openalex-snapshot
Data Resource Profile: Cardiovascular disease research using linked bespoke studies and electronic health records (CALIBER)
inferredcites →https://doi.org/10.1093/ije/dyw088openalex-snapshot
Selecting instruments for Mendelian randomization in the wake of genome-wide association studies
inferredcites →https://doi.org/10.1093/med/9780199669493.005.0005openalex-snapshot
International Statistical Classification of Diseases and Related Health Problems 10th Revision
inferredcites →https://doi.org/10.1093/nar/gkr972openalex-snapshot
Disease Ontology: a backbone for disease semantic integration
inferredcites →https://doi.org/10.1093/nar/gku1011openalex-snapshot
Disease Ontology 2015 update: an expanded and updated database of human diseases for linking biomedical knowledge through disease data
inferredcites →https://doi.org/10.1093/nar/gku1202openalex-snapshot
GRASP v2.0: an update on the Genome-Wide Repository of Associations between SNPs and phenotypes
inferredcites →https://doi.org/10.1093/nar/gku954openalex-snapshot
MoonProt: a database for proteins that are known to moonlight
inferredcites →https://doi.org/10.1093/nar/gkw1055openalex-snapshot
Open Targets: a platform for therapeutic target identification and validation
inferredcites →https://doi.org/10.1093/ptj/81.8.1464openalex-snapshot
Sifting the evidence—what's wrong with significance tests?
inferredcites →https://doi.org/10.1098/rsos.140216openalex-snapshot
An investigation of the false discovery rate and the misinterpretation of p -values
inferredcites →https://doi.org/10.1101/078972openalex-snapshot
MR-Base: a platform for systematic causal inference across the phenome using billions of genetic associations
inferredcites →https://doi.org/10.1111/j.1365-2796.2008.02015.xopenalex-snapshot
C‐reactive protein and coronary heart disease: a critical review
inferredcites →https://doi.org/10.1111/j.1476-5381.2010.01127.xopenalex-snapshot
Principles of early drug discovery
inferredcites →https://doi.org/10.1126/science.1260419openalex-snapshot
Tissue-based map of the human proteome
inferredcites →https://doi.org/10.1126/science.300.5625.1484bopenalex-snapshot
A Low Number Wins the GeneSweep Pool
inferredcites →https://doi.org/10.1126/science.302.5650.1484openalex-snapshot
One-Two Punch Leaves Physicists Gasping for Breath
inferredcites →https://doi.org/10.1126/science.aac8624openalex-snapshot
Health and population effects of rare gene knockouts in adult humans with related parents
inferredcites →https://doi.org/10.1126/scitranslmed.3001807openalex-snapshot
Electronic Medical Records for Genetic Research: Results of the eMERGE Consortium
inferredcites →https://doi.org/10.1126/scitranslmed.3002747openalex-snapshot
Reengineering Translational Science: The Time Is Right
inferredcites →https://doi.org/10.1126/scitranslmed.aad3744openalex-snapshot
A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease
inferredcites →https://doi.org/10.1126/scitranslmed.aaf2608openalex-snapshot
Disciplined approach to drug discovery and early development
inferredcites →https://doi.org/10.1126/scitranslmed.aag1166openalex-snapshot
The druggable genome and support for target identification and validation in drug development
inferredcites →https://doi.org/10.1136/bmj.322.7280.226openalex-snapshot
Sifting the evidence---what's wrong with significance tests? Another comment on the role of statistical methods
inferredcites →https://doi.org/10.1136/bmj.39048.407928.beopenalex-snapshot
Comparison of treatment effects between animal experiments and clinical trials: systematic review
inferredcites →https://doi.org/10.1136/bmj.d548openalex-snapshot
Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data
inferredcites →https://doi.org/10.1136/bmj.h5542openalex-snapshot
Why the drug development pipeline is not delivering better medicines
inferredcites →https://doi.org/10.1136/heartjnl-2014-305482openalex-snapshot
Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials
inferredcites →https://doi.org/10.1146/annurev-genom-090314-024956openalex-snapshot
Phenome-Wide Association Studies as a Tool to Advance Precision Medicine
inferredcites →https://doi.org/10.1146/annurev-pharmtox-010814-124614openalex-snapshot
How Good Is “Evidence” from Clinical Studies of Drug Effects and Why Might Such Evidence Fail in the Prediction of the Clinical Utility of Drugs?
inferredcites →https://doi.org/10.1146/annurev-pharmtox-011613-135943openalex-snapshot
The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication
inferredcites →https://doi.org/10.1146/annurev.biophys.31.082901.134314openalex-snapshot
The Natural History of Protein Domains
inferredcites →https://doi.org/10.1161/circgenetics.116.001616openalex-snapshot
Impact of Selection Bias on Estimation of Subsequent Event Risk
inferredcites →https://doi.org/10.1161/circulationaha.109.865444openalex-snapshot
Separating the Mechanism-Based and Off-Target Actions of Cholesteryl Ester Transfer Protein Inhibitors With CETP Gene Polymorphisms
inferredcites →https://doi.org/10.1161/circulationaha.109.923383openalex-snapshot
PLA2G7 Genotype, Lipoprotein-Associated Phospholipase A 2 Activity, and Coronary Heart Disease Risk in 10 494 Cases and 15 624 Controls of European Ancestry
inferredcites →https://doi.org/10.1186/1750-1172-7-s2-a10openalex-snapshot
Classification and coding of rare diseases: overview of where we stand, rationale, why it matters and what it can change
inferredcites →https://doi.org/10.1186/gb-2010-11-5-206openalex-snapshot
Between a chicken and a grape: estimating the number of human genes
inferredcites →https://doi.org/10.1186/s13023-015-0251-8openalex-snapshot
Rare diseases in ICD11: making rare diseases visible in health information systems through appropriate coding
inferredcites →https://doi.org/10.1212/wnl.47.6.1531openalex-snapshot
Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2
inferredcites →https://doi.org/10.1371/journal.pbio.1000294openalex-snapshot
Rare Variants Create Synthetic Genome-Wide Associations
inferredcites →https://doi.org/10.1371/journal.pbio.1000579openalex-snapshot
Synthetic Associations Created by Rare Variants Do Not Explain Most GWAS Results
inferredcites →https://doi.org/10.1371/journal.pbio.1000580openalex-snapshot
Synthetic Associations Are Unlikely to Account for Many Common Disease Genome-Wide Association Signals
inferredcites →https://doi.org/10.1371/journal.pbio.1002273openalex-snapshot
Risk of Bias in Reports of In Vivo Research: A Focus for Improvement
inferredcites →https://doi.org/10.1371/journal.pgen.1000072openalex-snapshot
A Genome-Wide Association Study Identifies Protein Quantitative Trait Loci (pQTLs)
inferredcites →https://doi.org/10.1371/journal.pgen.1004461openalex-snapshot
Cis and Trans Effects of Human Genomic Variants on Gene Expression
inferredcites →https://doi.org/10.1371/journal.pgen.1006706openalex-snapshot
Mapping of 79 loci for 83 plasma protein biomarkers in cardiovascular disease
inferredcites →https://doi.org/10.1371/journal.pgen.1006944openalex-snapshot
Genetic epidemiology and Mendelian randomization for informing disease therapeutics: Conceptual and methodological challenges
inferredcites →https://doi.org/10.1371/journal.pmed.0020124openalex-snapshot
Why Most Published Research Findings Are False
inferredcites →https://doi.org/10.1371/journal.pmed.0050201openalex-snapshot
Why Current Publication Practices May Distort Science
inferredcites →https://doi.org/10.1371/journal.pmed.1001489openalex-snapshot
Threats to Validity in the Design and Conduct of Preclinical Efficacy Studies: A Systematic Review of Guidelines for In Vivo Animal Experiments
inferredcites →https://doi.org/10.1371/journal.pone.0003081openalex-snapshot
Systematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias
inferredcites →https://doi.org/10.1377/hlthaff.2014.1029openalex-snapshot
Decline In Economic Returns From New Drugs Raises Questions About Sustaining Innovations
inferredcites →https://doi.org/10.2174/1574887110666150430151751openalex-snapshot
Financial Returns on R&D: Looking Back at History, Looking Forward to Adaptive Licensing
inferredcites →https://doi.org/10.3390/genes6010087openalex-snapshot
Genetics of Type 2 Diabetes—Pitfalls and Possibilities
inferredcites →https://doi.org/10.7326/0003-4819-130-12-199906150-00008openalex-snapshot
Toward Evidence-Based Medical Statistics. 1: The P Value Fallacy
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.